Specialist in Blood Banking - SBB(ASCP) Study Guide

Apply it

A bleeding patient has markedly reduced fibrinogen despite adequate platelet numbers. Explain why a fibrinogen-containing product addresses the measured deficit, while red cells address concurrent anemia and plasma supplies a broader mixture of coagulation factors.

Apply it

A patient needs irradiated red cells and has recurrent severe plasma-mediated allergic reactions. Irradiation and washing address separate indications; a leukoreduced label alone establishes neither requirement.

Apply it

A male allogeneic donor has hemoglobin of 12.7 g/dL and otherwise satisfactory screening. The hemoglobin criterion is unmet; negative infectious-disease results do not justify collection.

Apply it

Contrast an apheresis donor with perioral tingling during citrate return with a whole-blood donor who becomes pale, sweaty and bradycardic. The different cues direct investigation toward hypocalcemia or a vasovagal response.

Apply it

A red-cell shipment arrives within range, but its temperature record shows an unexplained excursion. Hold the units for assessment instead of accepting the final reading as proof of an intact cold chain.

Apply it

A group B patient needs plasma, and group B and group A units are available. Choose group B plasma because its expected anti-A has no corresponding target on the patient's B red cells.

Apply it

A conventional leukoreduced apheresis platelet QC sample contains 3.2 × 10^11 platelets and 6.0 × 10^6 leukocytes. Yield meets the stated criterion, but residual leukocytes exceed the stated limit and require nonconformance investigation.

Apply it

A patient's red cells do not react with anti-A or anti-B, but the plasma reacts strongly with routine group O cells. Investigate H antigen expression instead of assuming that an apparently group O forward type settles compatibility.

Apply it

Forward typing shows group A, but reverse typing reacts with A1 cells and not selected A2 cells. Correlate the pattern with subgroup testing and thermal reactivity before determining whether the antibody affects red-cell selection.

Apply it

A patient repeatedly types D positive but develops an antibody with apparent anti-D specificity after transfusion. Consider a partial D variant and investigate rather than rejecting alloanti-D solely because routine typing detected some D antigen.

Apply it

A patient had anti-Jka documented two years ago but now has a negative antibody screen. Retain the historical antibody in the selection plan and provide Jka-negative red cells with the required compatibility testing.

Apply it

An untreated panel suggests anti-Fya, but ficin-treated cells become nonreactive. Use the loss of Duffy reactivity as an expected treatment effect and complete identification with suitable untreated cells and antigen information.

Apply it

An antibody reacts with almost every routine panel cell, and selected rare cells support anti-k. Anticipate a rare-unit search and communicate the expected compatibility difficulty early instead of estimating availability from experience with anti-K.

Apply it

A pregnancy-associated Lewis phenotype differs from an earlier result. Consider temporary changes in antigen adsorption while independently verifying identity. For routine transfusion, assess compatibility at the 37°C IAT phase rather than requesting Lewis-negative units automatically.

Apply it

For routine support of a patient without sickle cell disease, select 37°C IAT-compatible units. For sickle cell disease with anti-M, select M-negative units. For maternal IgG anti-M reactive at 37°C, investigate fetal antigen risk and monitor the antibody.

Apply it

Assume two independent required negative phenotypes occur in 20% and 50% of available donors. The estimated eligible fraction is 10%; obtaining four suitable units would require screening about 40 units on average before other restrictions.

Apply it

A multiply transfused patient has repeatedly poor early platelet increments and demonstrable HLA antibodies. Contrast this investigation with a newborn whose thrombocytopenia is associated with maternal antibodies to a paternally inherited platelet antigen.

Apply it

A previously transfused patient has a negative screen before transfusion, followed days later by reappearance of a documented alloantibody and evidence of hemolysis. Link the timing to immune memory rather than assuming primary sensitization.

Apply it

A maternal antibody reacts at the antiglobulin phase and has an IgG specificity associated with fetal disease. Explain why placental passage matters, while an isolated maternal IgM antibody generally lacks the same direct fetal exposure.

Apply it

A sample has a C3-positive DAT, but the patient's hemoglobin and hemolysis markers are stable. Explain why complement coating warrants contextual investigation without establishing active, clinically important intravascular hemolysis on its own.

Apply it

A patient develops anemia and increased indirect bilirubin after transfusion, with a newly detectable IgG alloantibody but little plasma free hemoglobin. Consider predominantly extravascular clearance while investigating the reaction and excluding other causes of anemia.

Apply it

An anemia investigation shows no persuasive immune coating, while the history suggests an inherited red-cell metabolic disorder. Connect impaired energy production with membrane dysfunction and reduced survival instead of assigning an immune mechanism from anemia alone.

Apply it

A patient has recurrent mucosal bleeding, a normal platelet count and reduced factor VIII activity. Consider whether a VWF abnormality could connect impaired platelet adhesion with reduced factor VIII survival rather than assuming two unrelated disorders.

Apply it

A prolonged APTT corrects immediately in a mixing study but loses correction after incubation. Investigate a time-dependent inhibitor and appropriate factor studies, rather than treating immediate correction as definitive proof of a simple factor deficiency.

Apply it

A fetus at risk from maternal anti-K develops anemia with an unexpectedly limited erythropoietic response. Explain how suppression of red-cell production complements immune destruction and why the absence of brisk reticulocytosis is not reassuring.

Apply it

A D-negative pregnant patient has anti-D detected shortly after documented prophylaxis. Review prior results and administration history before labeling permanent alloimmunization, while recognizing that established immune anti-D represents a different situation from prevention in an unsensitized patient.

Apply it

A newborn has severe isolated thrombocytopenia, while the mother's platelet count is normal. Investigate maternal platelet alloantibodies and parental or neonatal antigen compatibility rather than dismissing an immune cause because the mother is not thrombocytopenic.

Apply it

A patient has an IgG-positive DAT but stable hemoglobin and no supporting biochemical evidence of hemolysis. Report and investigate the coating result appropriately without concluding that active autoimmune hemolytic anemia has been established.

Apply it

A group O recipient receiving a group A hematopoietic graft has a major mismatch because recipient anti-A targets donor A antigens. Reverse the pairing to identify a minor mismatch in which donor anti-A or donor-derived antibody production can target recipient A cells.

Apply it

A recently transfused patient shows mixed-field forward typing and an unexpected reverse reaction. Review prior typing and transfusion history, verify the specimen and investigate both cell populations and plasma reactivity before assigning the final ABO interpretation.

Apply it

A current negative screen triggers an electronic-crossmatch proposal, but the record contains prior anti-E. Recognize that the historical clinically significant antibody changes unit selection and compatibility requirements despite the current absence of detectable reactivity.

Apply it

A posttransfusion investigation requires assessment of the patient's circulating cells and a search for plasma alloantibodies. Use the DAT for cell-associated coating and an IAT-based investigation for antibodies capable of reacting with selected reagent or donor cells.

Apply it

An apparently negative tube crossmatch remains nonreactive after IgG-sensitized control cells are added. Treat the crossmatch as invalid, investigate washing and reagent steps, and repeat correctly before using that result to authorize routine release.

Apply it

A weak panel leaves anti-Jka unresolved, and the only nonreactive Jka-positive cell is heterozygous. Add appropriately selected homozygous Jka-positive cells rather than declaring anti-Jka excluded from the single weak-expression example.

Apply it

A mixed antibody pattern becomes simpler after ficin treatment, but the untreated panel retains additional reactions. Use the contrast to investigate more than one specificity, including antibodies whose antigens may have been destroyed by enzyme treatment.

Apply it

A patient receiving anti-CD38 therapy has panreactivity that disappears with conventional 0.2 M DTT-treated cells. With no established K-positive status, include K-negative unit selection and recognize that DTT treatment has not made every possible alloantibody detectable.

Apply it

A recently transfused patient needs an extended antigen profile for future matching. Recognize the mixed-cell limitation of current serologic phenotyping and consider genotyping to establish a more informative predicted patient profile for planning.

Apply it

An acid eluate reacts with all panel cells, but the last-wash control is also reactive. Investigate residual unbound antibody and repeat the preparation appropriately before interpreting the eluate as evidence of a panreactive red-cell-bound antibody.

Apply it

For a patient transfused two weeks earlier, use appropriately phenotyped allogeneic cells rather than mixed patient cells. To investigate anti-Jka, include an adsorption aliquot using Jka-negative cells and assess residual reactivity with suitable Jka-positive cells.

Apply it

A maternal antibody titer appears higher after testing moves to another platform. Before attributing the difference to increased sensitization, compare methods and, where appropriate, test retained and current specimens together under the same validated conditions.

Apply it

A polyspecific DAT is positive. Testing with monospecific anti-IgG and anti-C3 shows complement alone, prompting a targeted investigation rather than reporting IgG coating that the specific reagent results do not demonstrate.

Apply it

Suspected Lewis reactivity disappears after soluble Lewis substance is added, while a parallel sample receiving the same volume of control diluent remains reactive. This supports selective inhibition; continue investigating any remaining reactions for additional antibodies.

Apply it

A new specimen types group B, while several verified historical specimens were group A. Investigate collection and labeling and obtain appropriate independent confirmation rather than repeatedly testing the same tube until its B result seems convincing.

Apply it

A patient has symptomatic anemia without evidence of a coagulation-factor or platelet deficit. Explain why red cells address the oxygen-delivery problem, while plasma and platelets would expose the patient to products that do not correct the identified deficiency.

Apply it

Counts rise from 10 to 20 × 10^9/L after 3.0 × 10^11 platelets in a patient with BSA 1.8 m². CCI = 10,000 × 1.8 ÷ 3.0 = 6,000, or 6.0 with SI increments. Repeat a timed assessment and investigate immune and nonimmune causes.

Apply it

Two bleeding patients have different patterns: one has broad coagulation-factor depletion, while the other has marked fibrinogen reduction. Explain why plasma and a concentrated fibrinogen source address different deficits rather than treating them as interchangeable volumes.

Apply it

A patient develops rigors and hypotension during red-cell transfusion. Stop the transfusion, assess urgently, verify identity and notify the transfusion service rather than continuing while waiting for a DAT or other laboratory result.

Apply it

Soon after transfusion begins, a patient develops back pain, hypotension and red plasma. Urgently investigate an acute hemolytic reaction, including patient-unit identification and ABO compatibility, while clinical stabilization proceeds without waiting for the completed laboratory workup.

Apply it

A patient initially responds to transfusion but develops anemia and increased bilirubin several days later, with anti-Jka now detectable. Compare pretransfusion records and investigate donor antigen exposure rather than assuming the anemia is simply failure of transfusion efficacy.

Apply it

An older patient develops dyspnea, hypertension and pulmonary edema after multiple components, with a markedly positive fluid balance and improvement after diuresis. These findings favor TACO while the team evaluates other possible causes of respiratory deterioration.

Apply it

A platelet recipient develops severe rigors and hypotension. Send the residual pack for microbiological investigation, obtain patient cultures and promptly initiate supplier notification. Simultaneously investigate hemolysis rather than assigning a benign febrile diagnosis.

Apply it

During an apheresis procedure, a patient develops perioral tingling and hand paresthesias. Consider citrate-associated reduction in ionized calcium and assess the procedure and patient, while checking for other explanations when the clinical pattern is atypical.

Apply it

Before elective surgery, a stable patient has anemia consistent with a treatable deficiency. Investigate and address the cause while planning blood conservation, rather than assuming that preoperative transfusion is automatically the best way to normalize the hemoglobin.

Apply it

A U.S. laboratory receives a difficult PT antibody challenge that it would normally refer if it were a patient specimen. Keep the PT work within the participating laboratory and follow PT reporting requirements instead of shipping it to a reference laboratory.

Apply it

A U.S. laboratory installs an unmodified FDA-cleared analyzer and plans immediate patient reporting after vendor training. Require appropriate local performance verification and documentation before clinical use; operator familiarity alone does not demonstrate acceptable analytical performance.

Apply it

A quantitative control has a mean of 200 units and a standard deviation of 6 units. Calculate a CV of 3%, then distinguish that relative imprecision from whether the mean agrees with the accepted target value.

Apply it

A technologist will perform a procedure likely to splash blood toward the face. Select appropriate eye and nose-mouth protection with other necessary PPE, rather than relying on gloves because the material is handled inside the laboratory.

Apply it

A service requires 5,760 productive hours annually, and each budgeted FTE supplies 1,600 productive hours. Calculate 3.6 FTE, then assess whether the proposed shift pattern and competencies can actually deliver the required coverage.

Apply it

Control cells fail after automated washing but react in the parallel manually washed preparation using the same AHG reagent. This localizes concern toward the washing process rather than proving reagent inactivity.

Apply it

A laboratory reduces platelet holdings and reports less outdating, but urgent requests increasingly require delayed deliveries. Evaluate both changes together and revise stock targets using demand and replenishment patterns instead of declaring success from waste reduction alone.